GLP-1R agonist withdrawal effect on weight loss and cardiovascular risks remains unmet need: GlobalData Read more
Empagliflozin reduces hospitalisation risk for heart-failure and cardiovascular death by 21 per cent, shows Boehringer Ingelheim’s Emperor-Preserved trial Read more